GM1 Ganglioside Therapy in Idiopathic Parkinson's Disease
Study of a Possible Neuroprotective/Neurorestorative Agent in Parkinson's Disease Patients
The Parkinson's Disease Research Unit at Thomas Jefferson University, in collaboration with Johns Hopkins University, is conducting a study to examine the extent to which GM1 ganglioside can improve symptoms, delay disease progression, and perhaps partially restore damaged brain cells in Parkinson's disease (PD) patients. GM1 ganglioside is a chemical that is normally found in the brain and is a normal part of the outer covering or membrane of nerve cells. In this study, funded by the National Institutes of Health, we will assess the effectiveness of GM1 compared to standard Parkinson's treatments. Clinical measures of motor and cognitive functioning will be assessed at Thomas Jefferson University in Philadelphia and Positron Emission Tomography (PET) imaging of the brain and the dopamine nerve endings will be assessed at Johns Hopkins University in Baltimore. At the beginning of the study, patients will be divided into 2 groups. One group will receive GM1 for 6 months and the other will receive placebo. At the end of this 6 month period, all patients will enter into a 2 year open extension study in which all patients will receive GM1. If you have idiopathic PD, mild to moderate symptoms, are between the ages of 39-85 years old, have not had surgery related to your Parkinson's disease, and are interested in participating in this study, please call 215-955-8700 or e-mail Parkinsons.Research@jefferson.edu.